Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

271.20CHF
24 May 2019
Change (% chg)

CHF1.70 (+0.63%)
Prev Close
CHF269.50
Open
CHF269.00
Day's High
CHF273.35
Day's Low
CHF269.00
Volume
924,128
Avg. Vol
1,661,117
52-wk High
CHF280.55
52-wk Low
CHF206.35

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.97
Market Cap(Mil.): CHF214,033.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.31

Financials

  ROG.S Industry Sector
P/E (TTM): 22.03 29.30 32.55
EPS (TTM): 11.25 -- --
ROI: 20.46 14.23 13.82
ROE: 46.88 15.46 15.25

BRIEF-Roche Says Entrectinib Shrank Tumours Harbouring NTRK, ROS1 Or ALK Gene Fusions In Children And Adolescents

* SAYS ITS PERSONALISED MEDICINE ENTRECTINIB SHRANK TUMOURS HARBOURING NTRK, ROS1 OR ALK GENE FUSIONS IN CHILDREN AND ADOLESCENTS Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

May 16 2019

BRIEF-Roche says Entrectinib Shrank Tumors Harboring NTRK, ROS1 or ALK Gene Fusions In Children And Adolescents

* GENENTECH’S PERSONALIZED MEDICINE ENTRECTINIB SHRANK TUMORS HARBORING NTRK, ROS1 OR ALK GENE FUSIONS IN CHILDREN AND ADOLESCENTS

May 15 2019

BRIEF-Roche Presents New Ocrevus Data

* ROCHE TO PRESENT NEW OCREVUS (OCRELIZUMAB) DATA ANALYSES SHOWING SIGNIFICANT REDUCTION OF DISABILITY PROGRESSION IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS AT THE AAN ANNUAL MEETING

May 08 2019

BRIEF-Roche to include new SMA drug data in U.S., Europe filings set for H2 2019

* SAYS IN THE DOSE-FINDING PART 1 OF FIREFISH STUDY, INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY SURVIVED AND ACHIEVED MILESTONES BEYOND THOSE EXPECTED IN NATURAL HISTORY OF DISEASE

May 07 2019

BRIEF-Roche Expands Partnership With Bio-Techne To Offer Drug Discovery Researchers New Chromogenic Detection Options For Mrna Ish Tissue Analysis

* ROCHE EXPANDS PARTNERSHIP WITH BIO-TECHNE TO OFFER DRUG DISCOVERY RESEARCHERS NEW CHROMOGENIC DETECTION OPTIONS FOR MRNA ISH TISSUE ANALYSIS

May 06 2019

BRIEF-Roche Launches New Diagnostic Test For Breast And Gastric Cancer Patients

* ROCHE LAUNCHES NEW VENTANA HER2 DUAL ISH COMPANION DIAGNOSTIC TEST FOR BREAST AND GASTRIC CANCER PATIENTS ELIGIBLE FOR TARGETED THERAPY Source text for Eikon: Further company coverage: (Berlin Speed Desk)

Apr 23 2019

BRIEF-Roche Holding AG Drugs Chief Says Hemlibra Approaching 10 Percent Market Share In Non-Inhibitor Hemophilia A Patients

* DRUGS CHIEF SAYS HEMLIBRA APPROACHING 10 PERCENT MARKET SHARE IN NON-INHIBITOR HEMOPHILIA A PATIENTS Source text for Eikon: Further company coverage:

Apr 17 2019

Roche sees no Brexit interruption for patients

ZURICH, April 17 Roche holding ag ceo says sales growth for hemlibra primarily driven by non-inhibitors patients Roche holding ag ceo says spark therapeutics acquisition planned to be completed in first half Roche holding ag ceo says still believes biosimilars will enter market in u.s. In second half Roche holding ag says sees continued "very strong" growth for ocrevus after entry of novartis's mayzent Roche holding ag drugs chief says gantenerumab for alzheimers remains a high risk

Apr 17 2019

Roche says $4.3 billion Spark offer still on track for June completion

ZURICH Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.

Apr 03 2019

UPDATE 2-Roche says $4.3 bln Spark offer still on track for June completion

* Roche says confident deal will still go through in H1 (Rewrites, adds company comment, shares, background)

Apr 03 2019

Earnings vs. Estimates